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http://dx.doi.org/10.1016/j.ccr.2012.10.012SUMMARYThe epithelial-mesenchymal transition (EMT) is required in the embryo for the formation of tissues for which
cells originate far from their final destination. Carcinoma cells hijack this program for tumor dissemination.
The relevance of the EMT in cancer is still debated because it is unclear how these migratory cells colonize
distant tissues to formmacrometastases.We show that the homeobox factor Prrx1 is an EMT inducer confer-
ring migratory and invasive properties. The loss of Prrx1 is required for cancer cells to metastasize in vivo,
which revert to the epithelial phenotype concomitant with the acquisition of stem cell properties. Thus, unlike
the classical EMT transcription factors, Prrx1 uncouples EMT and stemness, and is a biomarker associated
with patient survival and lack of metastasis.INTRODUCTION
Metastasis is still the cause of 90% of deaths from carcinomas
(Gupta and Massague´, 2006) and despite the efforts devoted
to understand the mechanisms that drive disseminated tumor
cells to colonize distant tissues, it remains the least understood
step of tumor progression. To form distant metastasis, cancer
cells must first dissociate from the primary tumor, invade adja-
cent tissues, and intravasate into lymphatic and blood vessels
to later colonize lymph nodes and distant organs. For invasion
to occur, there is evidence that carcinoma cells can undergo
a phenotypic transformation, the epithelial-mesenchymal transi-
tion (EMT; Nieto, 2011), which enables them to invade, intrava-Significance
Metastasis is the cause of the vast majority of cancer-associ
understood. The invasion and dissemination steps during car
endows cells with invasive abilities and the stem cell-like prope
However, it is unclear how these migratory cells colonize dist
important for metastatic colonization. The loss of the EMT ind
tumor-initiating abilities. Our results help reevaluate the potent
ing the EMT while supporting those aimed at targeting stem c
Cansate, and navigate through a network of thin vessels while
acquiring stem cell-like properties (Mani et al., 2008; Morel
et al., 2008; Wellner et al., 2009). Still, it is not clear how these
individual mesenchymal cells can then form distant macrometa-
stases, in particular because carcinoma metastases usually
present a well-differentiated epithelial phenotype. Clues as to
how this mesenchymal-to-epithelial plasticity may arise have
come from the study of embryonic development, where several
rounds of EMT and the reverse process, mesenchymal-epithelial
transition (MET), are responsible for the formation of many
tissues and organs (Yang and Weinberg, 2008; Thiery et al.,
2009). Indeed, although experimental evidence is still scarce,
some indications suggest that this might indeed occur in vivoated deaths, but the underlying mechanisms remain poorly
cinoma progression have been associated with EMT, which
rties required to initiate the formation of a secondary tumor.
ant territories. Here, we show that abrogation of the EMT is
ucer Prrx1 allows cancer cells to revert EMT while acquiring
ial benefits of current therapeutic strategies aimed at target-
ell properties in cancer cells.
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Figure 1. The Prrx1 Transcription Factor Induces a Full EMT In Vivo
(A) Dorsal view of the posterior region of stage HH10-11 chick embryos. The expression of Snail1, Snail2, and Prrx1 was detected by ISH. Note the comple-
mentary expression patterns. Lpm, lateral plate mesoderm; som, somites. Scale bar: 500 mm.
(B) Chick embryos were coelectroporated on the right hand side with an EGFP expressing construct and a vector expressing Prrx1 or an empty control vector at
stage HH4 and examined at stage HH10-11. The expression of Paraxis was detected by ISH and the expression of EGFP by immunofluorescence staining. Top
panels show the dorsal views and the middle panels show transverse sections taken at the level of the dotted lines after the ectopic expression of Prrx1. The
bottom panels show high power images of boxed areas. Note that the loss of the epithelial somitemarkerParaxis (black asterisk) occurs only in the electroporated
(EGFP) cells. Ect, ectoderm.; Som, somites Scale bars: 250, 50, and 10 mm for upper, middle, and lower panels, respectively.
(C) Expression of fibronectin and laminin and EGFP detection in transverse frozen sections of chick embryos electroporated with Prrx1 or the control vector. Note
the excess of fibronectin (red star) and the disruption of the basement membrane (white arrows) in the electroprated areas (green stars). Scale bar: 50 mm.
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et al., 2009).
The similarities between developmental and pathologic EMT
validate the embryo as an excellent model to find new clues
regarding the events driving tumor progression. Indeed, the
EMT has developed during evolution to allow cells to migrate
to their final target destination, which they colonize before
contributing to the formation of definitive differentiated organs
(Nieto and Cano, 2012), a concept very similar to the process
of metastatic colonization. Therefore, the reactivation of a devel-
opmental program such as the EMT can make tumor cells
competent to respond to internal and external cues that confer
them with a high degree of epithelial plasticity. The aim of this
study was to take advantage of the vertebrate embryo to get
further insight into the mechanisms of metastatic colonization,
focusing on epithelial plasticity and the acquisition of stem cell
properties.
RESULTS
Prrx1 Induces Full EMT in Embryos and Cancer Cells
In search for EMT inducers, we performed expression screening
for transcription factors associated with early mesodermal
tissues in the chick embryo. We previously showed that upon
delamination from the primitive streak, the subdivision of meso-
dermal territories was accompanied by the distribution of Snail1
and Snail2 expression (Sefton et al., 1998). However, we have
now found a subset of lateral plate mesodermal cells that did
not express either Snail1 or Snail2, but rather express the
paired-related homeobox transcription factor Prrx1 (Figure 1A).
Prrx1 is also expressed in the somites. Interestingly, the
somites also express Snail genes but, as in the lateral plate
mesoderm, they also show complementary expression patterns
(Figure S1A).
Prrx1 had previously been implicated in several develop-
mental processes and aspects of fibroblast behavior (Cserjesi
et al., 1992; McKean et al., 2003), we therefore examined
whether Prrx1 could be an EMT inducer. Ectopic expression
of Prrx1 in the chicken embryo, as Snail1, caused failure of
epithelial somite development, as assessed by morphology
and by the loss of expression of the somitic epithelial markers
Paraxis (Figures 1B and S1B) and Uncx4.1 (Figure S1C). This
defective epithelialization occurred in a cell autonomous
manner (Figure 1B) and was accompanied by the increase in
fibronectin deposition and the disappearance of the basement
membrane as assessed by laminin staining (Figure 1C), all
hallmarks of an EMT.
In addition to the paraxial (somitic mesoderm), Prrx1 ectopic
expression also prevented the epithelialization of the interme-(D) Prrx1 electroporation was carried out as in (B). Upper panels show the expres
(asterisk), more evident on the sections (middle panels). The bottom panels sho
fluorescence (red). Note the presence of the epithelial nephric duct (nd) at the left
middle panels) and 50 mm (bottom panels).
(E) BMP2-soaked beads (white stars) were implanted in the left lpm of chick embr
and in the sections that the expression of Snail1 and Prrx1 is stronger and expa
(bottom). Scale bars: 250 mm (upper panels) and 100 mm (lower panels).
(F) The expression of Prrx1 in TGF-b-treated MDCK cells transfected with the ind
Histograms in (E) and (F) show one representative of three independent experim
See also Figure S1.
Candiate mesoderm precluding the formation of its derivative, the
nephric duct (nd), as assessed by morphologic analysis and by
the absence of expression of both its specific marker Pax2
(Figure 1D, upper panels) and of the epithelial marker E-cadherin
(Figure 1D, lower panels).
Like Snail1, Prrx1 expression was induced by BMP2 in the
embryo (Figure 1E) and ectopic expression of either Snail1 or
Prrx1 did not influence that of the other gene (Figure S1D). There-
fore, BMP2 seems to induce Snail1 and Prrx1 in an independent
manner. The existence of two parallel activation pathways
triggered by members of the tumor growth factor (TGF)-b super-
family was confirmed in MDCK cells after treatment with TGF-b,
the main inducer of EMT transcription factors in epithelial cells
(EMT-TFs; Thiery et al., 2009). Accordingly, interfering with
Snail1 or Snail2 expression in MDCK cells did not prevent the
induction of Prrx1 by TGF-b (Figure 1F).
Because TGF-b could induce Prrx1 expression in MDCK cells,
we examined whether Prrx1 could induce EMT in these cultured
cells. Indeed, Prrx1-expressing MDCK cells adopted a mesen-
chymalmorphology concomitant with loss of E-cadherin expres-
sion and gain of vimentin (Figure 2A). In cultured wound-healing
assays, these MDCK-Prrx1 cells healed the wound much faster
than control cells (Figure 2B) and they could migrate through
collagen gels (Figure 2C). Unlike MDCK-mock cells that formed
prototypical epithelial ducts, MDCK-Prrx1 cells grown in 3D
matrigel cultures instead formed a network of mesenchymal
cells (Figure 2D). Moreover, these cells had downregulated
epithelial markers and they had gained the expression of mesen-
chymal markers, including some EMT-TFs (Figure 2E). Interest-
ingly, as already observed in living embryos, Prrx1 did not
influence Snail1 expression, as MDCK-Prrx1 cells are devoid of
Snail1 transcripts (Figure 2E).
Given the relationship between EMT and Prrx1, we analyzed
the expression of this factor in a panel of human cancer cell lines
and we found that it was associated with the mesenchymal
phenotype and invasive properties (Figures 2F and S2). Further-
more, when compared to the expression of other EMT-TFs in
these cell lines, we noted that PRRX1 expression was frequently
associated with that of TWIST1 in invasive cell lines, indicating
that both factors could cooperate in the induction of EMT
(Figures 2F and S2; data not shown).
To further characterize Prrx1 as an EMT inducer in vivo and to
explore its relationship with Twist1, we moved to the zebrafish
embryo, which is very amenable to gain and loss of function
studies. We found that among the Prrx and Twist family
members in the fish, prrx1a and twist1b show an expression
pattern very similar to that observed in the chick for Prrx1 and
Twist1. In particular, these two genes were also coexpressed
in the lateral plate mesoderm (lpm) (Figures 3A and 3B). Thesion of Pax2 detected by ISH. Note the absence of Pax2 on the right hand side
w DAPI stainings (blue) to visualize nuclei and E-cadherin detected by immu-
side but it is missing at the right side (asterisk). Scale bars: 500 mm (upper and
yos at stage HH7 that were examined 5 hr later. Note both in the whole mounts
nded close to the beads. The bar graph shows the result of real-time RT-PCR
icated siRNAs was measured by real-time PCR analysis.
ents and include the mean ± SD of technical triplicates.
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Figure 2. Prrx1 Induces a Full EMT in MDCK Cells Concomitant with the Acquisition of Migratory and Invasive Properties
(A) Phase-contrast images and images of immunofluorescence staining of indicated proteins of MDCK clones expressing Prrx1 or an empty vector (mock). Scale
bar: 50 mm.
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Prrx1 Loss Reverts EMT for Metastatic Colonizationgain of function induced by injecting prrx1amRNA into embryos
produced a dramatic phenotype, whereby lpm cells became
invasive and violated the embryonic boundaries to enter the
extraembryonic tissues. The position of the cells could be readily
detected by examining the expression of twist1b, with cells
found all around the yolk (Figure 3C, lower panels). Knockdown
of prrx1a by antisense morpholino oligonucleotide (MO) injection
(prrx1aMO1) produced the opposite effect to that of prrx1amRNA
injection, with cells being retained very close to the neural tube,
failing to migrate and colonize their normal territory (Figure 3D;
see also Figure S3 for morpholino specificity and efficiency). A
different MO against prrx1a (prrx1aMO2, see Figure S3) was
also tested giving similar results (not shown). We decided to
continue our experiments with MO1, which will be hereafter
referred to as prrx1aMO. The observed defects were specific to
Prrx1a silencing as this phenotype could be rescued by coin-
jection of prrx1aMO and prrx1amRNA (Figures 3E and 3G). Inter-
estingly, injection of twist1bMO could also rescue the Prrx1a
overexpression phenotype, suggesting that these genes coop-
erate to induce the invasive phenotype observed in the lpm,
the tissue in which they are coexpressed (Figures 3F and 3G).
Indeed, this is compatible with the finding that tissues other
than the lpm did not seem to be affected when prrx1a alone
was overexpressed (Figure 3C; prrx1amRNA). These results indi-
cate that Prrx1a also behaves as an EMT inducer in the fish
embryo and that its upregulation induces a prominent invasive
phenotype in vivo when acting in cooperation with Twist1b.
To further investigate the cooperation between Prrx1 and
Twist in conferring invasive properties, we examined the effect
of their downregulation in the invasive BT-549 human cancer
cell line, which expresses significant levels of both factors (Fig-
ure 2F) and lacks SNAI1 expression (Moreno-Bueno et al.,
2011). We found that transient RNA interference of PRRX1 or
TWIST1 compromised the ability of BT-549 cells to degrade
collagen, which was further diminished when both factors were
knocked-down simultaneously (Figure 3H). Three independent
siRNA sequences were tested in these experiments (not shown).
Conversely, in the TWIST1-positive, PRRX1-negative, and
noninvasive HBL-100 cells, PRRX1 transfection renders them
invasive, a phenotype that was diminished when the endoge-
nous expression of TWIST1 was downregulated (Figure 3I).
Together, our data indicate that PRRX1 also confers invasive
properties to cancer cells in cooperation with TWIST1.
Cells Must Lose Prrx1 to Metastasize
We next investigated the role of Prrx1 in tumorigenesis by inject-
ing MDCK-Prrx1 and control cells into the tail vein of immuno-(B) The migratory properties of MDCK-Prrx1 cells were tested in wound healing
(C) Invasive behavior of MDCK-Prrx1 cells in collagen-type-IV gels, as observed i
DAPI. Scale bar: 100 mm.
(D) Phase-contrast images showing the morphology of control and Prrx1-express
E-cadherin (E-Cad) antibodies, and counterstained with DAPI. Scale bar: 50 mm
(E) Real-time RT-PCR analysis of control and Prrx1-expressing MDCK cells show
Dsp, desmoplakin; and Ocln, occludin) and the activation of mesenchymal m
integrin a5) together with several EMT-TFs (Snail1, Snail2, Zeb1, Zeb2, and Twis
(F) Expression of PRRX1 and TWIST1 in a panel of human cancer cell lines and i
Histograms in (E) and (F) show one representative of three independent experim
See also Figure S2.
Cancompromised mice and we failed to detect metastatic lung foci
(not shown). Moreover, when PRRX1-positive BT-549 breast
tumor cells were similarly injected, we did not detect lung colo-
nization either (Figure 4A; shC). However, when PRRX1 was
stably silenced by short-hairpin interference mediated by lentivi-
ral infection, BT-549 cells consistently colonized the lung in all
animals, inducing metastatic foci (Figure 4A; shPR1). Likewise,
silencing both PRRX1 and TWIST1 in BT-549 cells induced
lung metastasis in 100% of animals and the number of foci
increased significantly (Figure 4A; shPR1-shTW1), indicating
that TWIST1 downregulation also favors metastasis formation.
However, TWIST1 silencing alone (shTW1) was not sufficient to
induce metastatic colonization in the presence of PRRX1 (Fig-
ure 4A). The lack of colonization of control or shTWIST1 cells
was not due to a failure in extravasation, since single GFP-
positive cells were detected 24–30 hr after intravenous injection
in the lung parenchyma in all conditions (Figure S4A). Quantifica-
tion of GFP-positive lesions in the lungs at necropsy on day 60
together with a fluorescence and histologic analysis confirmed
the presence of metastasis in mice injected with BT-549 cells
knocked-down for PRRX1 alone or for PRRX1 and TWIST1,
together with the absence of metastasis in mice injected with
control cells or knocked-down for TWIST1 alone (Figure 4B).
Interestingly, cardiac and mediastinal metastasis were also
observed at necropsy in one mouse in which both PRRX1 and
TWIST1 were downregulated (Figure S4B). Cells in which
PRRX1 alone was silenced still express TWIST1 (Figure S4C),
indicating that PRRX1 silencing in BT-549 cells is sufficient for
these cells to engraft the lung and therefore, for colonization in
experimental metastasis assays.
To test the role of PRRX1 in primary tumor formation and
in distant metastatic colonization in vivo, we orthotopically im-
planted the BT-549 cells into the right and left inguinal mammary
fat pads of athymic nudemice. The generation of primary tumors
closely paralleled the capacity of these cells tometastasize in the
previous experiments. Thus, while BT-549 control cells or those
in which only TWIST1 was downregulated never generated
tumors, downregulation of PRRX1 and TWIST1 or even of
PRRX1 alone was sufficient to enable tumor growth (Figure 4C).
The tumors that developed in mice bearing BT-549 cells lacking
both PRRX1 and TWIST1 were detected earlier than those with
PRRX1-defective BT-549 cells, although the growth rate was
similar in both cases (not shown). Primary tumors were always
confined to the mammary gland, with the fatty tissue facing the
tumor being almost intact and with a remarkable absence of
invasive cells at the tumor margin (Figure 4D). Consistent with
their deficient invasive ability (Figure S4D), no metastatic fociassays. Scale bar: 100 mm.
n Boyden chamber invasion assays. Nuclei of invasive cells are visualized with
ing MDCK cells in 3D culture. Cells were stained with phalloidin for F-actin and
(main pictures) and 15 mm (inset).
the repression of epithelial markers genes (Cdh1, E-cadherin;Cldn1, claudin 1;
arkers (Col1a1, collagen I; Vim, vimentin; Fn, fibronectin; Sparc; and Itga5,
t1) upon Prrx1 ectopic expression.
ts relationship with invasive properties.
ents and include the mean ± SD of technical triplicates.
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Figure 3. Prrx1 Overexpression Induces Massive Invasion in Zebrafish Embryos
(A) Expression of prrx1a and twist1b in zebrafish embryos at the 22-somite stage (lateral and dorsal views). nc, neural crest; lpm, lateral plate mesoderm; som,
somites. Scale bar: 200 mm.
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Prrx1 Loss Reverts EMT for Metastatic Colonizationwere detected in any organ at necropsy, even 4 months after
inoculation of BT-549 cells where PRRX1 alone or PRRX1 and
TWIST1 were downregulated. This is again reminiscent of the
situation in embryos, where PRRX1 loss prevents cells from
migrating to then colonize their normal territories. Interestingly,
metastatic growth was found in axillary lymph nodes in two out
six mice bearing BT-549 PRRX1- and TWIST1-deficient cells
(Figure 4C), compatible with the proposal that lymph node colo-
nization does not require EMT. As such, although individual
mesenchymal cells can invade lymph nodes, their colonization
can also occur through collective cell migration (Giampieri
et al., 2009).
The Loss of PRRX1 Reverts EMT and Induces
Stem Cell Properties
Having shown that the loss of PRRX1 was sufficient for meta-
static colonization, but that PRRX1 expression was important
for invasion, we examined the impact of its downregulation on
the behavior of cancer cells. We first found that the loss of
PRRX1 was indeed sufficient for BT-549 cells to revert EMT,
undergoing a MET in culture, evidenced by the changes in
morphology and actin filament reorganization (Figure 5A).
When grown in 3D Matrigel cultures, PRRX1-deficient BT-549
cells did not form mesenchymal networks like control cells, but
rather they formed spheroids that had lost vimentin expression,
expressed significant levels of E-cadherin and b-catenin at the
cell membrane and that secreted laminin I, indicative of the
formation of a basement membrane-like structure (Figure 5B).
A similar phenotype was observed in cells in which both
PRRX1 and TWIST1 were downregulated (Figure 5B). However,
TWIST1 downregulation in BT-549 cells was unable to revert the
EMT (Figure 5B). It is worth noting here that these cells still
express high levels of PRRX1 (Figure S4C). In summary, it
appears that the loss of PRRX1 is sufficient to revert the EMT,
even in the presence of other EMT inducers such as TWIST1.
We next asked whether the altered phenotype and the ability
of BT-549 cells to form metastasis in vivo following PRRX1
loss was at least partially due to a modification in the tumor-initi-
ating properties of the nontumorigenic BT-549 cells. Soft agar
cultures andmammosphere formation assays in ultralow attach-
ment plates were used to examine the cells’ ability to support
attachment-independent growth and to self-renew, respectively,
taken as indicators of tumor-initiating capacity. While BT-549
control cells were unable to grow in soft agar, silencing of
PRRX1 or of both PRRX1 and TWIST1 enabled these cells to(B) Double fluorescent ISH of transverse gelatin sections taken at the mid trunk le
(C–F) ISH for twist1b to detect lpm cells in zebrafish embryos. Lateral (left), dorsa
view of lpm cells of zebrafish embryos microinjected with a control morpholino
(prrx1aMO) (D), prrx1amRNA together with prrx1aMO (E), or twist1bMO together w
extraembryonic territories. A color code was assigned to the different phenotype
(gain of function); pink, LOF (loss of function/knockdown), pale gray, partial rescu
(G), Scale bar: 200 mm in left and middle, 100 mm in the right, and 10 mm in the in
(G) Quantitative analysis of the fish phenotypes shown in (C–F) and that ofmicroinje
cells after transient downregulation of PRRX1 and/or TWIST1 by siRNA transfec
BT-549 cells. Histograms represent the mean ± SD of three independent experim
(I) Analysis of cell invasion of collagen matrices after ectopic PRRX1 expression
HBL-100 cells. Histograms represent the mean ± SD of four independent experim
PR or pr, PRRX or prrx; TW or tw, TWIST1 or twist, respectively.
See also Figure S3.
Canform colonies (Figures 6A and 6B), and facilitated secondary
mammosphere formation (Figures 6C and 6D). The number of
mammospheres increased when TWIST1 was additionally
silenced, compatible again with a cooperation between these
two factors. However, TWIST1 downregulation alone was not
able to induce BT-549 cells to grow in soft agar or to form mam-
mospheres (Figures 6A–6D). This is compatible with the previous
finding that TWIST1 expression can endow cells with stem cell
properties (Mani et al., 2008; Morel et al., 2008). Importantly,
PRRX1 loss was sufficient to sustain mammosphere growth up
to at least six consecutive passages (not shown).
It has been shown that EMT inducers attenuate proliferation,
which may also compromise tumor growth (Vega et al., 2004;
Mejlvang et al., 2007). Similarly, we found that PRRX1 loss
enhanced cell division, like Snail1 loss, as evident both by the
increase in cell number and the expression of the mitotic marker
phospho-histone 3 (PH3; Prigent and Dimitrov, 2003) (Figures 6E
and 6F). A similar effect was observed when both PRRX1 and
TWIST1 were silenced. Again, in the presence of PRRX1,
TWIST1 downregulation was not able to significantly alter cell
growth (Figures 6E and 6F).
To further characterize the impact of PRRX1 loss, we exam-
ined the expression of the CD44 and CD24 cell surface markers,
given that their relative expression and the CD44high/CD24low
profile in particular, has been associated with stemness in both
normal mammary and breast cancer cells (Sleeman et al.,
2006). Silencing PRRX1 or PRRX1 and TWIST1 converted
BT-549 cells (mostly CD44+/CD24+ double-positive) into
CD44high cells (Figure 6G), indicative of a stem cell phenotype
(Marotta et al., 2011). Therefore, PRRX1 downregulation was
sufficient to shift cells toward a population of CD44+ single-posi-
tive cells. By contrast, TWIST1 downregulation decreased CD44
expression. As CD24was almost abrogated from the cell surface
after PRRX1 silencing, we wondered whether PRRX1 could
regulate its expression. We found that PRRX1 loss leads to an
almost complete downregulation of CD24 transcription. By
contrast, TWIST1 downregulation increases the levels of CD24
transcripts, pointing again to an antagonistic role between
PRRX1 and TWIST1 in relation to the acquisition of stem cell
properties (Figure 6H).
If PRRX1 loss is sufficient to induce stem cell properties in
a non-tumorigenic cell line, ectopic expression of PRRX1 in
tumorigenic PRRX1-negative cells may have a negative impact
on their stem cell properties. To test it, we chose the tumorigenic
and highly metastatic MDA-MB-231 cell line (from now onvel shows the coexpression of prrx1a and twist1b in the lpm. Scale bar: 50 mm.
l (middle), and transverse gelatin sections (at the level of the dotted lines, right)
(MOC) or prrx1a mRNA (prrx1amRNA) (C), a prrx1a morpholino oligonucleotide
ith prrx1amRNA (F). nt, neural tube. Red arrowheads indicate invasive cells in
s (boxes on the right) as follows: yellow, WT (wild-type) and rescue; gray, GOF
e. This color code was also used for the quantification of phenotypes shown in
sets.
ction of a control mRNA (RFP). (H) Invasive properties of BT-549 human cancer
tion. Invasion is represented relative to that observed in control (siC-treated)
ents (**p < 0.01 compared to the control condition).
(PR1) and/or downregulation of endogenous TWIST1 expression (siTW1) in
ents (p = 0.083 PR1+siC versus siC; p = 0.082 PR1+siTW1 versus PR1+siC).
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Figure 4. PRRX1 Expression Regulates the
Tumorigenic and Metastatic Potential
(A) Experimental lung metastasis in Balb/c nude
mice 60 days after injection of BT-549 cells.
(B) Representative GFP-positive foci in lungs
(upper panels) and H&E sections of the lungs
(lower panels). Scale bars: 1 mm (upper panels)
and 200 mm (lower panels).
(C) Primary xenografts generated from BT-549
cells on the days indicated after double inguinal
intramammary fat pad (i.m.f.p.) injection (1 3 106
cells/injection site).
(D) Representative H&E sections of tumors from
mice injected with BT-549 shPRRX1 (left) or
shPRRX1-shTWIST1 cells (right). Scale bar:
100 mm.
C, control; PR, PRRX; TW, TWIST.
See also Figure S4.
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Prrx1 Loss Reverts EMT for Metastatic ColonizationMDA-231), which expresses EMT-TFs but is devoid of PRRX1
and TWIST1 (Figures 2F and S2). As expected, stable PRRX1
ectopic expression in MDA-231 cells alone or together with
TWIST1 (Figure 7A) did not have any impact on the morphology
of these already mesenchymal cells (Figure 7B). However, both
the number of colonies formed in soft agar cultures and particu-
larly, the number of secondary and tertiary mammospheres
significantly decreased upon PRRX1 ectopic expression
(Figures 7C–7F). Interestingly, all these effects were reinforced
by the additional ectopic expression of TWIST1 (Figures 7C–
7F). Furthermore, MDA-231 cells (mostly CD44+ single positive)
lose CD44 expression and shift toward a CD44/CD24
double-negative population (Figure 7G). Hence, as hypothe-716 Cancer Cell 22, 709–724, December 11, 2012 ª2012 Elsevier Inc.sized, the effect of ectopically expressing
PRRX1 in MDA-231 cells is opposite to
that found after PRRX1 downregulation
in BT-549 cells.
Collectively, our data indicate that the
loss of PRRX1 alone is sufficient to revert
EMT, inducing a MET accompanied by
the acquisition of stem cell properties
and increased proliferation, all important
events for metastatic colonization.
PRRX1 Expression Is Associated
with Good Prognosis and
Metastasis-Free Disease
Our data from the studies in mice indicate
that the loss of PRRX1 is associated with
the development of metastases. There-
fore, we wanted to know whether there
was any relationship between the level
of PRRX1 expression and metastasis in
human patients. We analyzed publically
available data sets and found that low
PRRX1 transcription was associated
with a poor relapse-free survival (RFS) in
breast adenocarcinoma (Chin et al.,
2006) (Figure 8A) and lung squamous
cell carcinoma (SCC) (Raponi et al.,2006) (Figure 8A). Furthermore, low expression of both PRRX1
and TWIST1 associate with a lower RFS in lung SCC (Figure 8B).
In contrast, there was no association between RFS and expres-
sion of TWIST1 alone or of SNAI1 (Figure S5A).
Consistent with our data in embryos and cancer cell lines,
a statistically significant association was found between
PRRX1 and TWIST1 expression in human breast adenocarci-
noma and in two series of lung SCC (Chin et al., 2006; Raponi
et al., 2006; Larsen et al., 2007) (Figure 8C). Similarly, and again
as in embryos and tumor cells, no association was found
between PRRX1 and SNAI1 expression (Figure 8C). Further-
more, significant correlations were evident between strong
PRRX1 expression and increased RFS either alone or in
F-
ac
tin
D
AP
I
A shPRRX1 1TSIWThslortnoChs shPR-shTW
F-
ac
tin
D
AP
I
Vi
m
en
tin
D
AP
I
E
-c
ad
β-
ca
te
ni
n
La
m
in
in
D
AP
I
B
Figure 5. PRRX1 Knockdown in Cancer
Cells Induces a Mesenchymal-to-Epithelial
Transition and Spheroid Formation
(A) Phase-contrast and phalloidin staining images
showing the phenotype of BT-549 cells trans-
fected with indicated shRNAs. Scale bars: 50 mm.
(B) Confocal images depicting the phenotype of
the different BT-549 cells transfected with indi-
cated shRNAs grown in 3D matrigel cultures and
assessed for the presence of epithelial (E-cadherin
and b-catenin), mesenchymal (vimentin), and
extracellular matrix (laminin I) markers. DAPI
staining (blue) was used as a nuclei reporter. Scale
bar: 50 mm. PR, PRRX; TW, TWIST.
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Prrx1 Loss Reverts EMT for Metastatic Colonizationcombination with TWIST1 expression in breast carcinoma using
a Log-rank-p-value method in the breast and lung series
mentioned and in an additional breast series (Pawitan et al.,
2005). The analysis of the Ur-Rehman (2011) data set available
at the Online Breast Cancer Knowledgebase (ROCK) (Experi-
mental Procedures) including 1570 human samples (Table S1)
confirmed these findings.
We also observed a statistical correlation between PRRX1
downregulation and progression to the metastatic disease.
Analyzing the Chin’s breast adenocarcinoma data set (Chin
et al., 2006) we found that remarkably, metastasis did not
develop in close to 90% of the tumors with medium/strong
PRRX1 expression (Figure 8D). The combination of strong
TWIST1 expression with strong PRRX1 expression did not
increase the percentage of metastasis-free tumors.Cancer Cell 22, 709–724, DFinally, after the analyses of the
different data sets, we examined the
expression of PRRX1 in 113 high-grade
infiltrating breast ductal carcinoma (IDC)
included in a tissue microarray (TMA).
We found that around one third of the
tumors analyzed showed significant
PRRX1 expression (Figures 8E and S5B)
and interestingly, that metastasis did not
develop in over 90% of these tumors (Fig-
ure 8F). These data are fully consistent
with those found in our analyses of the
data sets mentioned above. Thus, con-
sidering that all the data sets and the
tissue microarrays used correspond to
primary tumors, our observations indicate
that strong PRRX1 expression could be
considered as an independent marker of
good disease prognosis.
DISCUSSION
We have identified an EMT inducer that
can trigger the full process in living
embryos and human cancer cells. There
are several features that make Prrx1
unique when compared to other well-
known EMT-TFs, which expand our
understanding of the complexity under-lying metastatic processes, and help to reconcile conflicting
results that have challenged the significance of EMT and
stemness.
Prrx1 induces EMT in a manner independent of Snail1.
Both during embryonic development and tumor progression,
a temporal activation hierarchy drives the onset and mainte-
nance of the mesenchymal program, with Snail1 situated high
in the list. While Snail1 is required for the triggering of the EMT,
other EMT-TFs reinforce and maintain the mesenchymal state
(Peinado et al., 2007; Olmeda et al., 2008; Casas et al., 2011;
Tran et al., 2011). However, we found that Snail1 does not influ-
ence Prrx1 expression nor does Prrx1 modulate the expression
of Snail1. Interestingly, we have observed that the same
signaling molecule induces Prrx1 and Snail1 either in the embryo
(BMP) or in epithelial cells (TGF-b). Hence, a single signal canecember 11, 2012 ª2012 Elsevier Inc. 717
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Figure 6. PRRX1 Knockdown Induces the Acquisition of Stem Cell Properties in Cancer Cells
(A) Representative fluorescence images showing the ability to induce colony formation in soft agar 15 days after seeding. Insets are low magnification images.
Scale bars: 100 mm (main pictures) and 500 mm (inset).
(B) Quantification of soft agar colonies above 50 mm in diameter. Histograms represent the mean ± SD of three independent experiments (*p < 0.05, compared to
the control condition).
(C) Phase-contrast images showing the mammosphere-forming capacity of different BT-549 cells. Scale bars: 50 mm (main pictures) and 200 mm (inset).
(D) Quantification of secondary mammospheres as the number formed/103 cells seeded. Histograms represent themean ± SD of three independent experiments
(**p < 0.01; ***p < 0.001 compared to the control condition).
(E) Growth curve of different BT-549 cells. Graphics shows a representative experiment (n = 3).
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Prrx1 Loss Reverts EMT for Metastatic Colonizationsimultaneously and independently activate Prrx1 and Snail1
expression, and therefore, trigger parallel and probably nonre-
dundant EMT pathways.
Our data show that Prrx1 is essential for the acquisition of
invasive properties and indeed, when silenced in embryos, lpm
cells fail to migrate. Similarly, there is no sign of cellular or local
invasion in primary tumors generated by PRRX1-deficient
BT-549 cells, even though both lpm cells and PRRX1-deficient
human cells still express other EMT-TFs, including Twist1. Our
data show that Prrx1 is essential for the acquisition of invasive
properties and that Prrx1 cooperates with Twist1 in driving
invasion in embryos and cancer cells. This is consistent with
the described role of Twist in invasion and particularly, in the
formation of invadopodia (Yang et al., 2004; Eckert et al.,
2011). Once more, these findings support the cooperation
between EMT-TFs, both during development and in cancer
(Olmeda et al., 2008; Tran et al., 2011). Our data also reinforce
the concept that EMT is important for the invasive behavior of
the primary tumor, generating individual delaminating cells and
subsequent tumor progression. Indeed, the loss of PRRX1 in
BT-549 cells results in the formation of primary tumors without
invasion and distant metastasis when orthotopically injected in
the inguinal mammary fat pads. This is in agreement with the
finding that abrogating classical EMT-TFs such as Snail1and
Snail2 prevents individual cell migration and therefore attenuates
invasion and subsequent distant metastasis when tested in
similar experiments (Olmeda et al., 2008). Interestingly, albeit
not commonly, lymph node metastases were found in PRRX1-
TWIST1-deprived cells, consistent with the proposal that the
EMT is not required for lymph node metastasis (Giampieri
et al., 2009), albeit individual cells generated by EMT can also
populate the lymph nodes.
A crucial difference between Prrx1 and other EMT-TFs is that
Prrx1-induced EMT does not concur with the described induc-
tion of stem cell-like properties concomitant with Snail-, Twist-,
or Zeb-mediated mesenchymal transitions (Mani et al., 2008;
Morel et al., 2008; Wellner et al., 2009). On the contrary, it is
PRRX1 loss rather than gain in cancer cells that is accompanied
by the acquisition of stemness-related capabilities, including
anchorage-independent growth, mammosphere formation,
increased cell proliferation, and the conversion from a mostly
CD44+/CD24+ double-positive population to CD44high single-
positive cells. CD44high/CD24low is the described profile for
breast cancer stem cells associated with the most aggressive
and metastatic types (Marotta et al., 2011).
Importantly, the loss of PRRX1 in mesenchymal cancer cells
induces a complete reversion to the epithelial phenotype, even
in the presence of classical EMT inducers. As such, our data
show that abrogation of the EMT is important for metastatic
colonization and this phenotype reversion concurrent with the
aforementioned acquisition of stem cell-like properties upon
PRRX1 downregulation favors metastatic colonization. This(F) Quantification of cells undergoing mitosis as assessed by PH3 staining 16 hr
(G) BT-549 control cells and those in which PRRX1, TWIST1, or both had bee
CD24 by FACS.
(H)CD24 transcript levels observed in BT-549 control cells or in those where PRR
of three independent experiments.
C or Ctrol, control; PR, PRRX; TW, TWIST.
Canobservation is similar to the finding that the MET process is
essential for fibroblasts to acquire stem cell properties during
cellular reprogramming (Li et al., 2010, Samavarchi-Tehrani
et al., 2010), linking MET and stemness rather than EMT and
stemness as described during the mesenchymal transition trig-
gered by classical EMT-TFs. Our data also show that EMT and
stemness can be independently regulated, but it is clear that
they can coexist in some contexts such as in the migrating
cancer stem cells and in early embryonic development. Indeed,
EMT can induce the loss of epithelial characteristics of tropho-
blast stem cells while maintaining self-renewal and pluripotency
(Abell et al., 2011), as shown for the classical EMT-TFs during
tumor progression. However, it is worth noting that Snail2
(Slug) and Sox9 cooperate in the acquisition of themesenchymal
mammary stem cell state, with Snail2 essentially inducing the
EMT and Sox9 facilitating entry into the stem cell state (Guo
et al., 2012). All these findings indicate that EMT-TFs, or at least,
the mesenchymal phenotype and stemness can coexist, as
initially proposed following studies on colon carcinomas from
which the concept of ‘‘migrating cancer stem cells’’ arose (Bra-
bletz et al., 2005). However, the coexistence of these combined
traits also implies phenotypic plasticity, because our data indi-
cate that mesenchymal cells must revert to the epithelial pheno-
type to form the typical well-differentiated metastases while
maintaining stemness, as suggested previously (Chaffer et al.,
2006; Dykxhoorn et al., 2009; Celia`-Terrassa et al., 2012;
Brabletz, 2012). If MET is required for metastatic colonization,
the loss of classical EMT-TFs would also convey the potential
loss of stem cell properties associated with tumor-initiating
capacity, thereby impairing metastatic colonization. Our findings
showing that PRRX1 loss induces both MET and stemness, and
provides a mechanism that favors metastatic progression.
The fact that EMT and stemness are uncoupled in PRRX1-
induced EMT again supports the existence of a parallel nonre-
dundant EMT pathway mediated by PRRX1 in cancer cells and
the requirement of PRRX1 loss for the development of distant
macrometastases. As already mentioned, PRRX1 loss promotes
stemness, thereby favoring tumor-initiating capacities when
PRRX1 itself and the other EMT-TFs are downregulated after
extravasation at the secondary organ to favor MET. By contrast,
high PRRX1 expression can preclude progression to the meta-
static state due to both a deficiency in tumor-initiating capacity
and the persistence of an EMT state. As such, the unique asso-
ciation of strong PRRX1 expression in primary tumors with
metastatic-free disease and good RFS in patients with different
types of carcinoma, such as breast adenocarcinomas and lung
SCC supports this proposal. On the one hand this suggests
that strong PRRX1 expression in primary tumors could be used
as diagnostic of good prognosis and on the other hand, that
therapies aimed at targeting EMT might in fact promote meta-
static colonization once cells have already delaminated from
the primary tumor. Finally, the independent regulation of EMTafter cell seeding. Histograms shows a representative experiment (n = 3).
n downregulated were evaluated for their surface expression of CD44 and
X1, TWIST1 or both were downregulated. Histograms represent the mean ± SD
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Figure 7. PRRX1 Ectopic Expression Impairs Stem Cell Properties in Cancer Cells
(A) Relative expression of PRRX1 and TWIST1 in MDA-231 control cells and in those transduced with viruses to ectopically express either PRRX1 or PRRX1 plus
TWIST1. One representative of three independent experiments is shown and includes the mean ± SD of technical triplicates.
(B) Phase-contrast and phalloidin staining images showing the phenotype of control MDA-231 cells or of those in which PRRX1 has been ectopically expressed
alone or together with TWIST1. Scale bars: 100 mm (upper panel) and 50 mm (lower panel).
(C) Representative fluorescence images showing the ability of MDA-231 control cells and that of those with ectopic expression of PRRX1 or PRRX1 plus TWIST1
to form colonies in soft agar 30 days after seeding. Insets are low magnification images. Scale bars: 100 mm (main pictures) and 500 mm (inset).
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peutic strategies aimed at targeting stemness.
EXPERIMENTAL PROCEDURES
Human Breast Cancer
The analysis of PRRX1 expression was performed using a total of 113
retrospective IDC from the Pathology Department of MD Anderson Cancer
Center (MDACC) Madrid, Spain. All samples were grade 3. Patients underwent
surgery between 2005 and 2006. Two different tumor areas from each sample
were included into a tissue microarray (TMA) according to manufacturer’s
procedures. The mean patient age at surgery was 57.2 years (range, 38–85
years). The HsPRRX1 probe was amplified by PCR from total cDNA and
subcloned into a pGEMT-easy vector (Promega). In situ hybridization (ISH)
of TMA sections was performed as described previously (Nieto et al., 1996)
with some modifications. Briefly, 5 mm sections were deparaffinized in xylene
and rehydrated in descending ethanol series. Slides were permeabilized with
10 ug/ml of proteinase K for 5 min at room temperature and prehybridized in
hybridization buffer without probe for 3 hr and incubated with digoxigenin-
labeled riboprobe overnight at 60C. The following day, sections were washed
in 2X SSC/50% formamide for 4 hr at 60C. Hybridized probes were detected
using an alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche,
1:1000) in the presence of substrate nitroblue tetrazolium (NBT) 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) to produce a blue precipitate at the site of
hybridization. Sections were photographed under a Leica DMR microscope
(Leica, Wetzlar, Germany).
This study was performed following standard ethical procedures of the
Spanish regulation (Ley de Investigacio´n Orga´nica Biome´dica, 14 July 2007).
All participants in this study gave written informed consent, and the study
was approved by the Institutional Review Boards of MDACC Madrid.
Embryos
AB and Tup-Lof wild-type zebrafish strains were maintained at 28C
under standard conditions and the embryos were staged as described previ-
ously (Kimmel et al., 1995). Fertilized hen eggs were purchased from the
Granja Gilbert (Tarragona, Spain) and incubated in a humidified incubator at
37.5C. Chick embryos were staged according to Hamburger and Hamilton,
1951 (HH).
Cell Lines
MCF7, MDA-MB-231, MDA-MB-435S, A375P, HBL-100, MDA-MB-468,
SKBR3, and BT-549 human tumor cell lines and MDCK dog kidney cells
were purchased from the ATCC (Virginia, USA) and were cultured as described
in Supplemental Experimental Procedures. The names of MDA cell lines have
been reduced in the text for convenience.
Electroporation of Chicken Embryos and BMP2 Treatment
Chick embryos were electroporated with different expression constructs at
stage HH4 as described previously (Acloque et al., 2011). In all experiments,
the nonelectroporated side of the embryo served as a control. Human re-
combinant BMP2 protein (obtained from R&D Systems) was loaded onto
heparin acrylic beads at a concentration of 0.2 mg/ml. See also Supplemental
Experimental Procedures.
Morpholino Oligonucleotide and mRNA Injections
All MOswere obtained fromGene Tools and theywere used as described else-
where (Nasevicius and Ekker, 2000). The dose was chosen after testing the
efficiency of MO1 in preventing splicing (Figure S3). The specificity of the(D) Quantification of soft agar colonies above 50 mm in diameter. Histograms repr
compared to the control condition).
(E) Phase-contrast images showing the ability to form mammospheres of the dif
(F) Quantification of tertiary mammospheres as the number formed/103 cells see
(*p < 0.05; **p < 0.01 compared to the control condition).
(G) Analysis of CD44 and CD24 surface expression by FACS.
C, control; PR, PRRX; TW, TWIST.
CanMOs was checked by cloning the MO sequence in front of the EGFP coding
sequence and assessing the decrease in GFP expression after coinjection
with the corresponding MO. For overexpression analyses, embryos were
injected with mRNAs synthesized for prrx1a coding sequence. Rescue exper-
iments were performed by coinjecting mRNA plus MOs. See Supplemental
Experimental Procedures for details.
Whole-Mount In Situ Hybridization
Whole-mount ISH was carried out essentially as described previously (Nieto
et al., 1996). See Supplemental Experimental Procedures for details of the
probes used.
Viral Production and Cell Infections
Human cDNA containing the coding sequence of PRRX1was subcloned in the
pBABE-neo retroviral vector. Retroviral production and infection were carried
out as previously described (Mani et al., 2008). After infection, MDA-231 or
HBL-100 cells expressing either pBabe-neo (empty vector) or pBabe-neo-
PRRX1 were selected with 400 mg/ml G418 for 2 weeks. The lentiviral vector
containing the human TWIST1 ORF sequence was obtained from Open
Biosystems (OHS5898-101004920). Lentiviral plasmids containing shRNAs
were purchased from Open Biosystems and are listed as the following:
Human shPRRX1 (RHS3979-9588052 and RHS3979-9588055), and Human
shTWIST1 (RHS3979-9587949 and RHS3979-9587951). Lentiviral superna-
tants were produced using a viral packaging system that includes the psPAX2
and pM2DG plasmids (purchased from Open Biosystems). Two days after
transfection, the viral supernatants were collected and used to infect BT-549
and MDA-231 cells, which were then selected with 2 mg/ml puromycine. The
empty pLKO.1 vector was used as a control and in all cases, the cells were
also infected with the empty pGIPZ vector (obtained from Open Biosystems)
as a reporter of EGFP expression. For BT-549 cells, at least two independent
pools were generated in each case and the cultured cells were initially tested
for changes in morphology, expression, and invasive properties. Different
pools behaved similarly and for each condition, one was chosen for the in vivo
experiments.
Total RNA Extraction, cDNAs Isolation, and QRT-PCR Analysis
All the protocols are described in detail in the Supplemental Experimental
Procedures.
Generation and Characterization of Prrx1-Expressing Stable Cell
Lines
Stable transfectants were generated in MDCK cells and selected for 2 weeks
with 400 mg/ml G418. Five independent clones were analyzed for pcDNA3-
mPrrx1 and three for pcDNA3 alone (mock). Where indicated, cells were
transfected with siRNAs using Lipofectamine RNAiMAX according to the
manufacturer’s instructions (Invitrogen). Three independent siRNA sequences
were tested. See Supplemental Experimental Procedures for more details and
primer sequences.
Immunofluorescence
The methods used are described in the Supplemental Experimental
Procedures.
Tumor Growth and Histologic Studies
Mouse studies were carried out with the approval of the IDIBELL Animal Ethics
Committee (Procedure 4587 AFF) and in accordancewith the Spanish National
Health and Medical Research Council’s guidelines and the AALAC for the care
and use of laboratory animals. Details are provided in the Supplemental Exper-
imental Procedures.esent the mean ± SD of three independent experiments (*p < 0.05, ***p < 0.001
ferent MDA-231 cells. Scale bars: 50 mm (main pictures) and 200 mm (inset).
ded. Histograms represent the mean ± SD of three independent experiments
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Figure 8. Strong PRRX1 Expression in Breast Carcinomas and Lung SCC Is Correlated with the Lack of Metastases and Increased RFS
(A) Kaplan-Meier plots showing the association between PRRX1 expression and RFS using data sets from the Chin breast adenocarcinoma series (Chin et al.,
2006) and from a series of lung SCC (Raponi et al., 2006).
(B) Kaplan-Meier plots showing theassociationbetweencombinedhighPRRX1andhighTWIST1expressionwith increasedRFS from the lungSCSdatabase in (A).
(C) Correlation between PRRX1 and TWIST1 expression in a breast adenocarcinoma and two independent lung SCC data sets.
(D) Statistical association between either PRRX1 alone or PRRX1 and TWIST1 together with metastasis.
(E) Representative examples of ISH forPRRX1 in a retrospective grade 3 infiltrating ductal breast carcinoma series (n = 113) included in a tumormicroarray (TMA).
Lower panels show high power images. Scale bars: 200 mm (upper panels) and 50 mm (lower panels).
(F) Statistical association between PRRX1 expression and metastasis formation from the expression analysis of the TMA shown in (E).
*n (%), number of cases (percentage); ns, nonsignificant.
See also Figure S5 and Table S1.
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Formigration assays cells were seeded in six-well culture dishes at a density of
1 3 106 cells/well. A wound was made in the center of the culture 24 hr later,
and phase-contrast pictures were taken at different intervals. Invasion assays
on collagen type-IV gels were performed as described previously (Cano et al.,
2000). Briefly, 35,000–50,000 cells of each type were seeded onto the upper
surface of the filters in modified Boyden chambers. After 7 or 16 hr incubation
for BT-549 and HBL-100 respectively, cells attached to the lower part of the
filters were fixed in methanol, stained with 4,6-diamidinophenylindole (DAPI),
and counted. Longer incubation times for HBL-100 cells were required
because they are noninvasive.
Soft Agar Assays and Mammosphere Cultures
For details, see the Supplemental Experimental Procedures.
Cell Proliferation and Cell Cytometry Analysis
Analyses of cell proliferation and cell cytometry were carried out as described
in the Supplemental Experimental Procedures.
Metanalysis
To validate the metastatic prediction model, several independent data sets
of breast carcinoma (See Chin et al., 2006; Pawitan et al., 2005) and lung
SCC series (Raponi et al., 2006; Larsen et al., 2007) were analyzed. The
breast and lung microarrays, and the clinical data were obtained from
ICR and GEO databases, respectively. In addition, the Ur-Rehman data
set, publicly available in ROCK (http://www.rock.icr.ac.uk) was also used
in the analysis. The Ur-Rehman data set was a collection of independent
published breast cancer data sets containing 1,570 samples analyzed
with the U133 Affymetrix platform arrays, all of them were normalyzed using
the same Robust Multi-array Average method. The statistical survival
analysis associated to the breast and lung samples was performed using
ROCK (http://www.rock.icr.ac.uk) and SPSS software (SPSS), respectively.
Kaplan-Meier plots of the RFS curves are represented using log-rank tests.
The expression values of PRRX1, TWIST1, and SNAI1 was categorized
using upper quartile (25% against rest). The Chi-square contingency test
Yates correction, or Fisher’s exact test, was used to determine the statis-
tical significance of the relationships between PRRX1 expression and
TWIST1 expression, and metastasis. Values of p < 0.05 were considered
statistically significant. These analyses were carried out using the SPSS
17.0 for statistical software.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.10.012.
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